Create Free Account

By creating account you will get access to hot stocks & personalised emails

PharmAust Ltd

Healthcare AU PAA

0.205AUD
-0.015(6.82%)

Last update at 2024-05-01T00:16:00Z

Day Range

0.200.21
LowHigh

52 Week Range

0.070.54
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -6.21156M -1.70821M -1.33731M -1.36199M -1.61704M
Minority interest - - - - -
Net income -6.21156M -1.70821M -1.33731M -1.36199M -1.66486M
Selling general administrative 4.30M 4.74M 3.85M 4.24M 4.39M
Selling and marketing expenses - - - - -
Gross profit 2.04M 3.07M 1.92M 2.95M 3.34M
Reconciled depreciation 0.33M 0.31M 0.30M 0.27M 0.17M
Ebit -2.62422M -1.61970M -1.25832M -1.24350M -1.56922M
Ebitda -2.29767M -1.30477M -0.95835M -0.96886M -1.39679M
Depreciation and amortization 0.33M 0.31M 0.30M 0.27M 0.17M
Non operating income net other - - - - -
Operating income -3.25377M -1.62023M -1.27304M -1.24679M -1.56922M
Other operating expenses -7.35786M -5.50172M -4.47933M -4.87459M 5.93M
Interest expense 0.08M 0.09M 0.08M 0.12M 0.05M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.08M 0.00054M 0.01M 0.12M 0.05M
Net interest income -0.00084M -0.08797M -0.06427M -0.11850M -0.03002M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.08M 1.22M 1.60M 1.05M 0.05M
Total revenue 2.82M 3.38M 2.14M 3.20M 3.67M
Total operating expenses 5.74M 5.82M 4.71M 5.12M 5.60M
Cost of revenue 0.79M 0.31M 0.23M 0.25M 0.33M
Total other income expense net -2.51012M 1.13M 1.52M 0.93M -0.04782M
Discontinued operations - - - - -
Net income from continuing ops -6.21156M -1.70821M -1.33731M -1.36199M -1.55122M
Net income applicable to common shares -6.21156M -1.70821M -1.33731M -1.36199M -1.55122M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 6.13M 10.08M 10.95M 10.75M 8.60M
Intangible assets 3.11M 3.11M 3.14M 3.11M 3.11M
Earning assets - - - - -
Other current assets 0.08M 0.02M 0.02M 0.03M 0.06M
Total liab 2.24M 2.23M 2.07M 2.22M 1.14M
Total stockholder equity 3.89M 7.84M 8.88M 8.53M 7.46M
Deferred long term liab - - - - -
Other current liab 0.42M 0.56M 0.35M 0.50M 0.04M
Common stock 57.63M 55.34M 55.33M 53.77M 51.39M
Capital stock 57.63M 55.34M 55.33M 53.77M 51.39M
Retained earnings -56.45889M -50.24733M -48.53912M -47.20181M -45.90564M
Other liab 0.00334M 0.03M 0.03M 0.04M 0.04M
Good will - - - - -
Other assets 0.32M - - - -
Cash 2.71M 2.42M 3.02M 2.88M 2.09M
Cash and equivalents - - - - 2.09M
Total current liabilities 1.35M 1.17M 0.91M 1.10M 0.92M
Current deferred revenue -0.15845M -0.34807M -0.14664M -0.31013M -
Net debt -1.65698M -1.03055M -1.74226M -1.40864M -1.76601M
Short term debt 0.16M 0.35M 0.15M 0.35M 0.14M
Short long term debt - 0.21M 0.04M 0.18M 0.14M
Short long term debt total 1.05M 1.39M 1.28M 1.47M 0.32M
Other stockholder equity -1.17382M -5.09661M -6.78732M -6.57062M 0.07M
Property plant equipment 0.00164M 3.24M 3.45M 3.57M 2.47M
Total current assets 3.02M 3.73M 4.36M 4.07M 3.02M
Long term investments - - - - -
Net tangible assets 0.78M 4.73M 5.74M 5.42M 4.35M
Short term investments 0.02M 0.00422M 0.00422M 0.00429M 0.00429M
Net receivables 0.15M 0.19M 0.24M 0.30M 0.26M
Long term debt - - 0.00000M 0.04M 0.18M
Inventory 0.09M 1.04M 1.01M 0.86M 0.61M
Accounts payable 0.93M 0.60M 0.56M 0.56M 0.74M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.72M 2.75M 2.09M 1.96M 1.91M
Additional paid in capital - - - - -
Common stock total equity - - - 53.77M 51.39M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -3.10912M -6.34747M -6.59697M -6.67619M -0.00000M
Deferred long term asset charges - - - - -
Non current assets total 3.11M 6.35M 6.60M 6.68M 5.58M
Capital lease obligations 1.05M 1.17M 1.24M 1.25M -
Long term debt total 0.89M 1.04M 1.13M 1.12M 0.18M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.03493M -0.04338M -0.13804M -0.03023M -0.14672M
Change to liabilities 0.32M 0.04M 0.00201M -0.11602M 0.06M
Total cashflows from investing activities -0.03493M -0.04338M -0.13804M -0.03023M -0.14672M
Net borrowings -0.35433M 0.05M -0.32073M -0.29402M -0.10103M
Total cash from financing activities 1.89M 0.77M 1.22M 2.09M 1.92M
Change to operating activities -0.03668M 0.00850M -0.00706M 0.07M -0.04138M
Net income -6.21156M -1.70821M -1.33731M -1.36199M -1.66486M
Change in cash 0.29M -0.60465M 0.14M 0.79M 0.22M
Begin period cash flow 2.42M 3.02M 2.88M 2.09M 1.88M
End period cash flow 2.71M 2.42M 3.02M 2.88M 2.09M
Total cash from operating activities -1.56418M -1.33226M -0.93797M -1.27000M -1.55401M
Issuance of capital stock 2.24M 0.72M 1.54M 2.38M 2.02M
Depreciation 0.33M 0.31M 0.30M 0.27M 0.17M
Other cashflows from investing activities -0.00017M 0.00000M -0.03632M - -
Dividends paid - - - - -
Change to inventory -0.00422M -0.03492M -0.15050M -0.24575M -0.03780M
Change to account receivables -0.04090M 0.06M 0.06M -0.03884M -0.01049M
Sale purchase of stock 2.24M 0.72M 1.54M 2.38M 2.02M
Other cashflows from financing activities -0.03493M 0.21M -0.13804M -0.03023M -0.14672M
Change to netincome 4.08M -0.01382M 0.20M 0.14M -0.14174M
Capital expenditures 0.03M 0.04M 0.14M 0.03M 0.15M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.04511M 0.02M -0.09477M -0.28459M 0.69M
Stock based compensation -0.01001M -0.04634M 0.16M 0.05M -
Other non cash items 4.32M 0.06M 0.10M -0.18265M 1.38M
Free cash flow -1.59911M -1.37564M -1.07600M -1.30023M -0.14672M

Fundamentals

  • Previous Close 0.22
  • Market Cap96.78M
  • Volume434204
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.69599M
  • Revenue TTM3.71M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 2.48M
  • Diluted EPS TTM-0.02

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PAA
PharmAust Ltd		 -0.015 6.82% 0.20 - - 37.19 18.49 48.29 -15.9698
CSL
CSL Ltd		 -1.46 0.53% 275.30 35.08 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 -0.1 0.66% 14.95 763.75 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd		 -0.33 1.72% 18.87 16.04 38.46 11.63 13.15 10.65 12.39
MSB
Mesoblast Ltd		 0.04 4.55% 1.03 - 769.23 116.88 1.12 126.11 -19.3368

Reports Covered

Stock Research & News

View All

Profile

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

PharmAust Ltd

5/3 Brodie Hall Drive, Bentley, WA, Australia, 6102

Key Executives

Name Title Year Born
Dr. Roger Aston B.Sc., BSc (Hons), Ph.D. Exec. Chairman & Acting CEO 1956
Mr. Sam Michael Wright A.C.I.S., ACIS, AFin, DipAcc, M.A.I.C.D., MAICD Fin. Director, Company Sec. & Non-Exec. Director 1978
Mr. Robert Charles Bishop LLB (Hons) Exec. Director NA
Ms. Fiona Milner Gen. Mang. of Epichem Pty Ltd NA
Dr. Gary Pitt Head of Chemistry NA
Dr. James Rixson Head of Production NA
Mr. Sam Michael Wright A.C.I.S., ACIS, AFin, DipAcc, M.A.I.C.D., MAICD Finance Director, Company Secretary & Non-Executive Director 1978
Mr. Robert Charles Bishop LLB (Hons) Executive Director NA
Ms. Fiona Milner General Manager of Epichem Pty Ltd NA
Dr. Michael Thurn Ph.D. CEO & Director NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.